Doxapram Exposure Was Not Associated With Adverse Neurodevelopmental Outcomes in Very Low Birth Weight Infants: A Monocentric Retrospective Cohort Study
Thomas Müller, Alexandros Rahn, Sabine Pirr, Corinna Peter, Carolin Böhne, Bettina Bohnhorst · 2026
Read Doxapram Exposure Was Not Associated With Adverse Neurodevelopmental Outcomes in Very Low Birth Weight Infants: A Monocentric Retrospective Cohort Study by Thomas Müller, Alexandros Rahn, Sabine Pirr, Corinna Peter, Carolin Böhne, Bettina Bohnhorst (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13460644.txt.
Description
Thomas Müller and co-authors wrote a cohort study from 2026 on whether doxapram, a breathing stimulant for premature babies, leaves marks on the developing brain. The drug rescues apnea when caffeine and airway pressure fall short, but its long-term safety was unproven. The team followed very low birth weight infants born at or before thirty-two weeks at one center. One hundred forty exposed babies were matched against two hundred eighty unexposed ones by birth year.
At two years of corrected age, development scores did not differ between the groups. Death rates were also alike, and no dose pattern emerged: babies who got more drug fared no worse. Growth and nerve outcomes matched as well. Adjusted models kept the null result. The authors read this as reassurance, not proof, and call for a prospective randomized trial to settle the drug's safety.
Catalog record
| CREATOR | Thomas Müller, Alexandros Rahn, Sabine Pirr, Corinna Peter, Carolin Böhne, Bettina Bohnhorst |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |